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Purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 
impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti- 
COVID-19 vaccines have been developed with an unprecedented speed. While these vac-
cines have good efficacy and are safe, the experience with their use is limited and hence the 
knowledge of rare side effects. Identifying rare complications is important for future safe use 
of these vaccines.
Materials and Methods: Here, we report a case of a 82-year old patient with dementia 
who was admitted to a nursing home in the Netherlands. After vaccination with COVID-19 
vaccination, physical examinations and lab tests were performed.
Results: She had a reactivation of hepatitis C infection after vaccination with the mRNA- 
based Pfizer–BioNTech COVID-19 vaccine. This reactivation manifested with jaundice, loss 
of consciousness, hepatic coma and death.
Conclusion: This reactivation of hepatitis C virus after vaccination with the Pfizer– 
BioNTech COVID-19 vaccine suggests a need for critical consideration of individuals with 
prior HCV infection and considered for COVID-19 vaccination.
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Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (Covid- 
19) emerged as a pandemic at the beginning of 2020.1 Several vaccines against 
Covid-19 have been developed with unprecedented speed, some of them using 
novel technologies such as mRNA-based approaches. While large Phase 3 trials 
provided evidence for efficacy and safety, registration of post-licensing is crucial 
for future safe use of these novel technologies. Here, we report a case of a hepatitis 
C virus reactivation following COVID-19 vaccination using the mRNA-based anti- 
COVID19 vaccine produced by BioNTech/Pfizer.
Materials and Methods
A 82 years old woman with dementia [Alzheimer’s disease] was admitted to 
a nursing home in the Netherlands in 2020. Her medical history included hepatitis 
C infection [2007], hepatitis B infection [1980], diabetes mellitus type 2 [2005], 
essential hypertension [2001], osteoarthritis [2007], portal hypertension with eso-
phageal varices [2015], hepatic cirrhosis with thrombocytopenia, and allergy to 
wasp sting [2014]. She had slightly increased liver enzymes [AST, ALT, GGT, 
ALP], but normal bilirubin [since 2011]. The patient never tested positive for 
COVID - 19.
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On 21 February 2021, the patient was vaccinated 
against COVID-19 using Pfizer–BioNTech COVID-19 
vaccine [first dose]. During the first two days after the 
first vaccination, no symptoms or signs were observed.
Results
On day 3 after vaccination jaundice, somnolence and chills 
were noticed. On clinical examination there was an 
obvious jaundice of skin and sclerae; her consciousness 
was decreased. Rectal temperature 38.1C, heart rate 92 
bpm, oxygen saturation 95% [no dyspnea], blood pressure 
105/93 mmHg. Two hours later rectal temperature was 
37.4C, consciousness was somewhat improved, whereas 
other vital signs remained abnormal. Color of urine and 
feces was normal. Blood glucose levels were normal.
Between day 4 and 10 the patient consciousness 
improved and the jaundice cleared.
After day 10 of follow-up manifest jaundice again 
increased, accompanied by severe pain in the upper right 
abdomen, irradiating to the upper left abdomen, followed 
by loss of consciousness, coma and death on day 23. 
Hepatitis C was confirmed by the blood test. Patient 
refused treatment with hepatitis C medication.
Blood test on day 5 showed: 
Total bilirubin 137 [ref 3–20 umol/l]
Conjugated bilirubin 102 [ref 0–4 umol/l]
Alkaline phosphatase 120 [ref 0–98 U/l]
Gamma-GT 87 [ref 0–38 IU/l]
Aspartate transaminase 113 [ref 0–31 U/l]
Alanine transaminase 92 [ref 0–34 U/l]
C-reactive protein 76 [ref 0–5 mg/l]
Leucocytes 81 [ref 40–100 109/l]
Hepatitis C PCR positive [269.229 IU/ml]
Hepatitis C antibodies positive
Hepatitis B sAg negative; no viral replication
Hepatitis B anti-HBs positive [51.3 mIU/ml]
Hepatitis B anti-HBc positive
A second blood test on day 14 showed a decrease of 
bilirubin and CRP levels, but a further increase of liver 
enzymes AST, ALT and ALP.
Discussion
An 82-year old woman with multiple morbidities had reacti-
vation of hepatitis C infection after vaccination with the 
mRNA-based Pfizer–BioNTech COVID-19 vaccine. 
Injection of fragments of mRNA that encode viral antigens 
induces a long-term immune response against COVID-19. 
Most frequently occurring side effects are mild, with transi-
ent fatigue and headache being the most common, followed 
by (in order of frequency): pain and swelling at the injection 
site, muscle aches, chills, joint pain, fever [more common 
after the second dose] and allergic reactions.2,3 However, the 
short-term experience with this new type of vaccines needs to 
be complemented by careful observation of the population 
after large-scale introduction of the vaccine, in order to 
monitor the occurrence of rare side effects.
In our patient a strong increase in HCV load occurred 
a few days after vaccination. While we cannot exclude 
a coincidental occurrence of the HCV load increase by 
chance after the vaccination, a causal relationship seems 
likely given the close temporal proximity of vaccine 
administration and the elevated HCV. An alternative 
explanation is that she used oxycodone, which may induce 
cholestasis and thereby possibly viral reactivation. 
However, low-dose (5 mg daily) oxycodone had been 
already started six weeks before vaccination, i.e. without 
a close temporal proximity to HCV reactivation.
In addition, one might argue that there had been 
a sustained viral response after the onset of hepatitis C in 
2007, which, however, did not cause jaundice. Rather, an 
inflammatory response to the vaccine (in combination with 
the presence of viral replication) could have been suffi-
cient to cause decay of liver cells, leading to her symptoms 
and severity of the disease. However, after the episode of 
hepatitis C in 2007, no other episodes of jaundice or other 
symptoms of liver disease occurred, apart from a stable 
slight increase in liver enzymes. Moreover, an episode of 
pneumonia six months before the current episode was not 
followed by any of these liver symptoms. However, in the 
absence of HCV viral load measurements between 2007 
and 2020, we cannot fully rule out this possibility.
The most likely explanation therefore is an HCV reacti-
vation, caused by the COVID-19 vaccination. It is known for 
other vaccines that they can cause virus reactivation, espe-
cially in immunosuppressed patients and patients undergoing 
cancer treatment, eg as described for the herpes zoster sub-
unit vaccine, causing reactivation of herpes zoster stromal 
keratitis.4 SARS-CoV-2 encoded proteins [and some anti- 
COVID-19 drugs] are able to induce reactivation of 
Kaposi’s sarcoma-associated herpesvirus.5
Hepatitis C virus reactivation has been described in 
patients receiving cancer treatments, in whom HCV reacti-
vation occurred in 23% of patients.6 Another study revealed 
that psoriasis patients with hepatitis C infection were at risk 
for HCV reactivation with the use of biologic therapies.7
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So far, no virus reactivations have been described after 
COVID-19 vaccination. We can only speculate on the 
mechanisms through which vaccination could have reacti-
vated HCV. One possibility, as in the case of Kaposi 
sarcoma-associated herpesvirus, is that SARS-CoV-2 
encoded proteins may cause reactivation of the hepatitis 
C virus. Alternatively, an indirect mechanism through 
induction of inflammation and cytokines, that would sub-
sequently influence viral replication, is also possible.
Finally, from another perspective, a COVID vaccina-
tion followed by jaundice may reveal [by supplementary 
diagnostics] a previously unrecognized but now reacti-
vated hepatitis C infection.
Conclusion
This study describes a case of hepatitis C reactivation 
following COVID-19 vaccination. The patient received 
no hepatitis C medication and died three weeks following 
COVID-19 vaccination of liver failure. No other cases 
with a history of HCV infection and cirrhosis with 
a similar fatal course following COVID-19 vaccination 
have been described. This suggests a need for critical 
consideration of individuals with prior HCV infection 
and considered for COVID-19 vaccination.
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